Donald E Tsai
Overview
Explore the profile of Donald E Tsai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
838
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lamanna N, Tam C, Woyach J, Alencar A, Palomba M, Zinzani P, et al.
EJHaem
. 2024 Oct;
5(5):929-939.
PMID: 39415923
Clinical bleeding events are reported here from 773 patients with B-cell malignancies receiving pirtobrutinib monotherapy from the phase 1/2 BRUIN study (ClinicalTrials.gov identifier: NCT03740529), either in the presence or absence...
2.
Shah N, Wang M, Roeker L, Patel K, Woyach J, Wierda W, et al.
Haematologica
. 2024 Oct;
110(1):92-102.
PMID: 39363864
Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment of B-cell malignancies, but intolerance has often led to their discontinuation. The phase I/II BRUIN study evaluated pirtobrutinib, a highly selective...
3.
Wierda W, Shah N, Cheah C, Lewis D, Hoffmann M, Coombs C, et al.
Lancet Haematol
. 2024 Jul;
11(9):e682-e692.
PMID: 39033770
Background: Richter transformation usually presents as an aggressive diffuse large B-cell lymphoma, occurs in up to 10% of patients with chronic lymphocytic leukaemia, has no approved therapies, and is associated...
4.
Roeker L, Woyach J, Cheah C, Coombs C, Shah N, Wierda W, et al.
Blood
. 2024 Jun;
144(13):1374-1386.
PMID: 38861666
Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). Patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) were treated with fixed-duration pirtobrutinib plus venetoclax (PV)...
5.
Roeker L, Coombs C, Shah N, Jurczak W, Woyach J, Cheah C, et al.
Acta Haematol
. 2024 Jun;
:1-17.
PMID: 38824917
Introduction: Pirtobrutinib, a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor, has demonstrated promising efficacy in B-cell malignancies and is associated with low rates of discontinuation and dose reduction. Pirtobrutinib...
6.
Nikiforow S, Whangbo J, Reshef R, Tsai D, Bunin N, Abu-Arja R, et al.
Blood Adv
. 2024 Apr;
8(12):3001-3012.
PMID: 38625984
Patients with Epstein-Barr virus (EBV)-positive posttransplant lymphoproliferative disease (EBV+ PTLD) in whom initial treatment fails have few options and historically low median overall survival (OS) of 0.7 months after allogeneic...
7.
Mato A, Woyach J, Brown J, Ghia P, Patel K, Eyre T, et al.
N Engl J Med
. 2023 Jul;
389(1):33-44.
PMID: 37407001
Background: Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase (BTK) inhibitor treatment, and new therapeutic options...
8.
Wang M, Jurczak W, Zinzani P, Eyre T, Cheah C, Ujjani C, et al.
J Clin Oncol
. 2023 May;
41(24):3988-3997.
PMID: 37192437
Purpose: Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent Bruton tyrosine kinase inhibitor (cBTKi)...
9.
Wang E, Mi X, Thompson M, Montoya S, Notti R, Afaghani J, et al.
N Engl J Med
. 2022 Feb;
386(8):735-743.
PMID: 35196427
Background: Covalent (irreversible) Bruton's tyrosine kinase (BTK) inhibitors have transformed the treatment of multiple B-cell cancers, especially chronic lymphocytic leukemia (CLL). However, resistance can arise through multiple mechanisms, including acquired...
10.
Mato A, Shah N, Jurczak W, Cheah C, Pagel J, Woyach J, et al.
Lancet
. 2021 Mar;
397(10277):892-901.
PMID: 33676628
Background: Covalent Bruton's tyrosine kinase (BTK) inhibitors are efficacious in multiple B-cell malignancies, but patients discontinue these agents due to resistance and intolerance. We evaluated the safety and efficacy of...